Blog

  • That Diamond Engagement Ring From Cristiano Ronaldo Is 50 Carats And Worth $3 Million, Appraisers Say

    That Diamond Engagement Ring From Cristiano Ronaldo Is 50 Carats And Worth $3 Million, Appraisers Say

    Topline

    The diamond ring soccer icon Cristiano Ronaldo used to propose to his longtime partner Georgina Rodriguez could be as large as 50 carats, appraisers told Forbes, making it larger than the famous sparklers given to Mariah Carey, Kim Kardashian and Lauren Sánchez.

    Key Facts

    Rodriguez announced the pair’s engagement after eight years of dating on Monday with a photo that focused on her ring.

    It drew instant headlines and attention—the sparking center stone reaches to Rodriguez’s knuckle—and appraisers told Forbes it’s among the “rarest and most exquisite diamonds in the world.”

    Kristian Spofforth, a jewelry specialist with Heritage Auctions, said the diamond seems to be an oval-cut stone of approximately 50 carats with a D colour grade—the highest on the scale—and likely a clarity of VVS1 or better.

    Traditional diamonds are valued in part by how closely they approach colorlessness on a scale from D to Z and based on their clarity, or flawlessness (a VVS1 is the second-highest clarity rating and means a stone has only minute flaws that are difficult for a skilled grader to see under 10x magnification).

    The metal used for Rodriguez’s ring isn’t immediately clear from images posted online, but Spodforth said “the setting is elegant, minimal and perfectly tailored to showcase the stone’s natural beauty.”

    Gemologist appraiser Deborah Villepigue said she estimates the center stone to be a little bigger, between 55 and 60 carats, and the ring to be worth roughly $3 million.

    Get Forbes Breaking News Text Alerts: We’re launching text message alerts so you’ll always know the biggest stories shaping the day’s headlines. Text “Alerts” to (201) 335-0739 or sign up here: joinsubtext.com/forbes.

    What We Don’t Know

    Who designed Rodriguez’s ring. Some have speculated it was made by Cartier, but no jeweler has yet claimed the work.

    How Does Georgina Rodriguez’s Ring Compare To Other Famous Engagement Rings?

    Few stars have flaunted diamonds bigger than Rodriguez’s, but two stand out. Rapper Gucci Mane famously gave his wife Keyshia Ka’oir a 60-carat, oval cut diamond ring in 2019 as an upgrade to the 25-carat ring he proposed with two years earlier, and Richard Burton gave Elizabeth Taylor a 69.42-carat, pear-shaped stone he purchased for her in 1969. Burton reportedly bought the diamond from Cartier for $1 million, the equivalent of about $8.6 million today. Rodriguez’s ring is larger than the initial Harry Winston ring Burton used to propose to Taylor in 1968, which featured a 33.19-carat Asscher-cut diamond. Burton reportedly outbid Winston himself for that ring for $305,000, the highest price ever paid at auction for a diamond ring at the time. Rodriguez’s ring also out-sizes some of the most-talked-about celebrity rings in recent memory, including Mariah Carey’s 35-carat emerald-cut ring from billionaire James Packer, which was designed by Wilfredo Rosado and valued at $10 million. Other famous rings include the $8 million, 15-carat cushion-cut diamond ring by Lorraine Schwartz that Kim Kardashian received from Kanye West, and the $5 million, 30-carat pink diamond billionaire Jeff Bezos used to propose to Lauren Sánchez. Sanchez was also spotted wearing another 30-to-40 carat oval diamond ring, estimated to be worth around $4 million, at her Venice wedding earlier this summer. Both of her rings were designed by Schwartz.

    Key Background

    Ronaldo and Rodriguez appeared publicly together for the first time in 2017 alongside his son from a previous relationship, Cristiano Jr. Six months later, in June, Ronaldo welcomed twins Eva and Mateo via surrogate. He has never shared the identity of the mother of his first three children. Rodriguez gave birth to her first child with Ronaldo in November 2017 and announced she was pregnant with twins in October of 2021. One of the children died in childbirth. The pair first sparked engagement rumors in November of 2018 and fans have speculated about their relationship status since. In July 2024, Ronaldo hinted that he and Rodriguez might have married after the soccer star referred to her as his “wife,” but his publicist told People, “At this time, I have no knowledge of whether or not Cristiano is married to Georgina.” Netflix chronicled the daily life of Rodriguez in a reality series called “I Am Georgina” that aired for three seasons.

    Forbes Valuation

    Ronaldo, 40, was ranked by Forbes as the world’s highest paid athlete this year. He is estimated to have made $275 million in the last year and, in 2020, became the first active team-sport athlete to surpass $1 billion in career earnings. In addition to a lifetime deal with Nike and other endorsements, Ronaldo earns money off the pitch from his CR7-branded clothing, accessories, hotels and gyms.

    Further Reading

    ForbesThe World’s 10 Highest-Paid Athletes 2025By Brett KnightForbesWhat To Know About Lauren Sánchez’ $300,000 Richard Mille Watch—And Why It Could Soon Be Even More Expensive.By Mary Whitfill RoeloffsForbesOakley Billionaire James Jannard Lists $65 Million Beverly Hills Home: See InsideBy Mary Whitfill Roeloffs


    Continue Reading

  • Google taps large language models to cut invalid ad traffic by 40% – Search Engine Land

    1. Google taps large language models to cut invalid ad traffic by 40%  Search Engine Land
    2. How we’re using AI in new ways to fight invalid traffic  The Keyword
    3. Google Has Been Quietly Using Gemini AI to Weed Out Ad Fraud and Invalid Traffic  Adweek
    4. Google Expands its Use of AI to Detect Invalid Ad Traffic  Yahoo Finance

    Continue Reading

  • CDC Director’s Vow to Rebuild Trust Meets Skepticism After Attack

    CDC Director’s Vow to Rebuild Trust Meets Skepticism After Attack

    US Centers for Disease Control and Prevention Director Susan Monarez vowed to rebuild trust with the American public after the agency was the target of a deadly shooting last week, but some staff were frustrated that she didn’t offer more information on safety.

    The gunman who shot nearly 200 rounds into four buildings and two security guard stands on the CDC campus Aug. 8 outlined his frustration with Covid vaccines before the rampage, according to the Georgia Bureau of Investigation. The attack occurred as medical misinformation is rampant in the US, fueling everything from political positioning to consumer purchases — and increasingly violent attacks.

    Continue Reading

  • CDC Director’s Vow to Rebuild Trust Meets Skepticism After Attack

    CDC Director’s Vow to Rebuild Trust Meets Skepticism After Attack

    US Centers for Disease Control and Prevention Director Susan Monarez vowed to rebuild trust with the American public after the agency was the target of a deadly shooting last week, but some staff were frustrated that she didn’t offer more information on safety.

    The gunman who shot nearly 200 rounds into four buildings and two security guard stands on the CDC campus Aug. 8 outlined his frustration with Covid vaccines before the rampage, according to the Georgia Bureau of Investigation. The attack occurred as medical misinformation is rampant in the US, fueling everything from political positioning to consumer purchases — and increasingly violent attacks.

    Continue Reading

  • Post-Hoc FUEL Trial Analysis Shows Udenafil Significantly Improves Exercise Capacity in Fontan Patients with Reduced Baseline Function

    Post-Hoc FUEL Trial Analysis Shows Udenafil Significantly Improves Exercise Capacity in Fontan Patients with Reduced Baseline Function

    SEOUL, South Korea, Aug. 12, 2025 /PRNewswire/ — A newly published post-hoc analysis of the landmark FUEL (Fontan Udenafil Exercise Longitudinal) Trial demonstrates that udenafil, a PDE5 inhibitor, significantly improves peak oxygen consumption (peak VO₂) in adolescents with single ventricle congenital heart disease (SV-CHD) who have undergone the Fontan procedure and have reduced exercise capacity.

    Published in the Journal of the American Heart Association: “Revisiting the Effect of Udenafil on Exercise Performance in Patients With Fontan Circulation: Results of a Post Hoc Analysis of the FUEL Trial”

    The original multinational, randomized, placebo-controlled Phase 3 FUEL trial demonstrated statistically significant improvements in key secondary endpoints – such as VO₂ at ventilatory anaerobic threshold (VAT) and myocardial performance index (MPI) – but narrowly missed statistical significance for the primary endpoint of peak VO₂ in the overall population. Recognition of a high performing “Super Fontan” subgroup prompted further analysis stratifying participants by baseline peak VO₂ (<80% vs. ≥80% of predicted) to assess whether initial exercise capacity influenced treatment response.

    Key findings from the post-hoc analysis:

    • In the 302 patients with baseline peak VO₂ <80% predicted (80% of the evaluable cohort), udenafil significantly improved peak VO₂ compared to placebo (p=0.021).
    • Significant improvements were also observed in VO₂ at VAT (p=0.023), work at VAT (p=0.032), and MPI (p=0.007).
    • A significant interaction between baseline exercise capacity and treatment effect for peak VO₂ (p=0.036) suggests that including high-functioning patients, whose physiologic ceiling may limit measurable gains, could have masked the full treatment effect in the original trial.

    “These results provide a possible physiologic explanation for the outcomes of the FUEL trial and support further investigation of udenafil in Fontan patients with reduced exercise capacity,” said Dr. David Goldberg, lead author and pediatric cardiologist at Children’s Hospital of Philadelphia. “This analysis highlights the need for a confirmatory clinical trial targeted to the large majority of Fontan patients who are most likely to demonstrate benefit using peak VO2 as the primary endpoint.”

    “Importantly, the absence of a detectable change in peak VO₂ among higher-functioning Fontan patients may reflect– what may be termed a ‘ceiling effect’ – rather than a lack of therapeutic response,” added Dr. Bryan H. Goldstein, senior author and Director of the Cardiac Catheterization Laboratory at UPMC Children’s Hospital of Pittsburgh. “These patients still achieve meaningful improvements in submaximal exercise measures such as VO₂ at VAT and MPI. Moreover, as these younger, high-performing individuals age and are further exposed to ongoing Fontan circulatory stresses, their exercise capacity with decline and therefore, the need for targeted pharmacotherapy will likely increase.”

    The findings highlight the importance of selecting appropriate endpoints and stratifying populations in rare disease trials. Informed by FUEL, the ongoing confirmatory phase 3 FUEL-2 trial focuses on Fontan patients with reduced baseline exercise capacity – those in whom changes in peak VO₂ are most reliably measurable.

    “This focused design increases the likelihood of demonstrating efficacy on the primary endpoint, while still capturing udenafil’s broader therapeutic potential,” said Dr. Rahul Rathod, Global Principal Investigator for FUEL-2 and Director of the Single Ventricle Program at Boston Children’s Hospital. “Given the strong link between peak VO₂ and long-term outcomes in Fontan patients, a +1.13 mL/kg/min improvement over six months is clinically meaningful and may influence disease progression.”

    The FUEL trial was supported by the National Heart, Lung, and Blood Institute (NHLBI) and Mezzion Pharma Co., Ltd., the regulatory sponsor of udenafil development for Fontan patients.

    About Mezzion

    Mezzion Pharma Co., Ltd. is a biopharmaceutical company developing therapies for rare and orphan diseases. Udenafil is currently being evaluated in the Phase 3 FUEL-2 trial for improving exercise performance in adolescents and young adults with Fontan circulation.

    For more information, please visit www.mezzion.com and www.FUEL2Study.com.

    Media Contacts:
    John Presser, Chief Business Officer – [email protected]
    Sung-Il Noh, Chief Financial Officer – [email protected]

    SOURCE Mezzion Pharmaceuticals, Inc

    Continue Reading

  • Duplantis breaks world pole vault record on Budapest return – worldathletics.org

    1. Duplantis breaks world pole vault record on Budapest return  worldathletics.org
    2. Duplantis sets new pole vault world record of 6.29m  RFI
    3. Mondo Duplantis soars to 6.29m world record in Budapest  Athletics Weekly
    4. Mondo Breaks Pole Vault World Record for 13th Time at Istvan Gyulai Memoria  FloTrack
    5. Mondo Duplantis raises his pole vault world record to 6.29 meters  Yakima Herald-Republic

    Continue Reading

  • OpenAI Movie Casts Chris O’Dowd to Join Andrew Garfield

    OpenAI Movie Casts Chris O’Dowd to Join Andrew Garfield

    Chris O’Dowd has joined the sprawling cast of Luca Guadagnino’s Artificial, Amazon MGM’s drama centered on the true-life story of artificial intelligence company OpenAI.

    Artificial has Andrew Garfield, Yura Borisov, and Monica Barbaro leading a cast that also includes Jason Schwartzman, Cooper Hoffman, Ike Barinholtz, Cooper Koch, Billie Lourd and Zosia Mamet. 

    The movie is being described as a comedic drama, although it is a dramatized recounting of the tumultuous period at OpenAI in 2023 that saw CEO Sam Altman fired and rehired in a matter of days.

    Altman co-founded OpenAI but in the fall of that year, amid mounting safety concerns regarding AI and reports of abusive behavior, he was ousted as the head of the company by his board. Five days later, after a revolt, he was reinstated. Garfield is playing Altman.

    Details for O’Dowd’s character are being kept in a data center.

    Simon Rich wrote the script and is producing alongside Heyday Films’ David Heyman and Jeffrey Clifford, as well as Jennifer Fox. 

    The movie is currently shooting.

    Artificial marks the first feature that O’Dowd is doing since 2022’s big-budget fantasy, Slumberland. The Tony Award–nominated and Emmy-winning actor most recently created, directed, and starred in the original Sky series Small Town, Big Story and is generating Emmy buzz for his Black Mirror episode “Common People.”

    He is represented by CAA, Gordon & French and 3 Arts. 

    Continue Reading

  • Gut bacteria can digest common food thickeners

    Gut bacteria can digest common food thickeners

    It turns out those cellulose-based thickening agents found in common foods can be digested.

    Researchers at the University of British Columbia have shown that our gut bacteria can feed on these large molecules – something thought to not be possible – thanks to enzymes that normally help us break down dietary fibre.

    “Researchers assumed that these thickening agents, which are artificial derivatives of natural cellulose, just pass right through the digestive system unaltered,” says Dr. Deepesh Panwar, a postdoctoral fellow at the Michael Smith Laboratories and lead author of the study published in the Journal of Bacteriology. “But our study provides a first glimpse at how these food additives are actually digested by our gut bacteria thanks to natural polysaccharides in our diets.”

    The complex structure of these cellulose derivatives is what makes them valuable as thickening agents in popular products like ketchup, salad dressing and even toothpaste. This structure is also why gut bacteria have a harder time breaking them down – and why in higher concentrations, they’re even used as laxatives.

    This new in vitro study, however, shows that if our gut bacteria are ‘primed’ with natural polysaccharides – long chains of sugars found in fruits, vegetables and cereals – the cellulose derivatives can be digested. This is because the natural polysaccharides activate enzymes that are produced on bacteria cell surfaces that can also break down artificial cellulose molecules.

    The findings don’t challenge the fact that these compounds are safe to consume, proven by years of testing and history of use. However, the new research suggests that more work should be done to explore the physical, chemical and biological effects of the digestion of cellulose derivatives by gut bacteria.

    One reason researchers may not have seen this before is because bacteria in the lab are often exposed to polysaccharides, including cellulose derivatives, in isolation, instead of in combinations that mimic our diet. On their own, these cellulose derivatives can’t activate the same enzymes, preventing their digestion.

    It was really unexpected for us to see that these cellulose derivatives are in fact used as a source of sugar for bacterial growth. It is always a surprise when a new finding goes against the conventional wisdom, in this case showing that these common additives are not just inactive thickeners.”


    Dr. Harry Brumer, professor in the Michael Smith Laboratories and Department of Chemistry

    Dr. Brumer also notes that the next steps in this research will be to look for this ability in a wider range of human gut bacteria, and eventually explore potential effects on nutrition in people.

    So, next time you pair a green salad with a sweet dressing, know that your gut bacteria are hard at work helping to break down all parts of your meal.

    Source:

    University of British Columbia

    Journal reference:

    Panwar, D., et al. (2025). Artificial cellulose derivatives are metabolized by select human gut Bacteroidota upon priming with common plant β-glucans. Journal of Bacteriology. doi.org/10.1128/jb.00198-25.

    Continue Reading

  • Dudley’s Russells Hall Hospital uses AI to help stroke patients

    Dudley’s Russells Hall Hospital uses AI to help stroke patients

    Joanne Writtle

    BBC Midlands Today

    Eleanor Lawson

    BBC News, West Midlands

    BBC A man with grey hair wearing a light green t-shirt lies in a hospital bed, propped up against a pillow. He is looking upwards.BBC

    Patrick Potter has benefitted from the use of AI at Russells Hall Hospital in Dudley

    Stroke patients at a hospital are receiving a faster diagnosis with the help of artificial intelligence (AI) technology.

    Russells Hall Hospital in Dudley introduced RapidAI into its stroke unit in May 2024, with the technology speeding up the triage process for patients by providing instant access to diagnostic imaging.

    Care minister Stephen Kinnock visited the hospital on Tuesday, where he saw the “potentially life-saving improvement” in action.

    One of the latest patients to benefit is Patrick Potter from Stourbridge, who had a stroke on Thursday and suffered a bleed on the brain.

    Mr Potter’s scan was sent straight to his consultant’s mobile phone, resulting in quicker diagnosis and treatment – and with a stroke, doctors say every minute counts.

    The 62-year-old said the technology was “absolutely brilliant”.

    “I don’t know to what extent or what damage it would have done to my brain,” he said.

    “Initially I was terrified because I’ve never had anything happen like that before, but within a few days [I was told] it looks like it’ll be able to recover and you’ll be okay.”

    A bald man with black glasses and a white shirt, with a blue tie tucked into the space between the buttons, stands on a hospital ward. Two women sit at a desk looking at computers behind him.

    Care minister Stephen Kinnock said the use of AI in the hospital was “a potentially life-saving improvement”

    While visiting the hospital on Tuesday, Kinnock said: “Within seconds of the scan taking place, the consultants are able to see exactly what the issue is in terms of what has caused the stroke.

    “That speed of information is then shared through an app with all the relevant consultants, the quicker they get the diagnosis, the quicker they can decide what treatment is required.”

    He added: “This use of AI can slash the time between someone showing symptoms of stroke to getting treatment by up to an hour – a potentially life-saving improvement. When it comes to strokes, every second counts.”

    Diagnosis within an hour

    The technology speeds up the triage process by providing instant access to diagnostic imaging, accompanied by preliminary reports for clinicians to quickly verify and act upon – significantly improving response times and outcomes.

    The technology also flags suspected strokes in patients that may not show traditional clinical signs, such as speech problems or a droopy face or eye.

    It means patients can receive potentially life-saving treatments earlier.

    Since its implementation at Dudley Group NHS Foundation Trust in May 2024, the technology has meant patients were able to be diagnosed within 40-60 minutes, which is up to 1 hour faster than diagnoses without AI.

    The government is planning to roll out the use of AI across the country as part of the NHS’s shift from analogue to digital systems, a 10-year plan called the Plan for Change.

    Kinnock said: “Artificial intelligence and digital tech are central to our 10 year health plan, helping patients be seen faster to improve outcomes so they can get home sooner.”

    Continue Reading

  • Relacorilant Plus Nab-Paclitaxel May Serve As New Standard of Care in Platinum-Resistant Ovarian Cancer

    Relacorilant Plus Nab-Paclitaxel May Serve As New Standard of Care in Platinum-Resistant Ovarian Cancer

    Domenica Lorusso, MD, PhD

    The addition of nab-paclitaxel to relacorilant (Abraxane) further improved progression-free survival (PFS) vs nab-paclitaxel alone in patients with platinum-resistant ovarian cancer, meeting the primary end point of the phase 3 ROSELLA trial (NCT05257408) and demonstrating the potential for this combination to improve upon the current standard of care (SOC), according to Domenica Lorusso, MD, PhD.1

    Data from the study, which were previously presented at both the 2025 ASCO Annual Meeting and the 2025 ESMO Gynecological Cancers Congress, revealed that the median PFS in the overall population was 6.54 months (95% CI, 5.55-7.43) and 5.52 months (95% CI, 3.94-5.88) with relacorilant plus nab-paclitaxel (n = 188) vs nab-paclitaxel (n = 193), respectively (HR, 0.70; 95% CI, 0.54-0.91; P = .0076). At 6 months, the respective PFS rates were 52% vs 42%. At 12 months, respective PFS rates were 25% vs 13%.

    “More than 60% of these patients had [previously] received PARP inhibitors,” Lorusso explained during an interview with OncLive®. “We know that these patients are very difficult to treat, as [many] of these patients are [not only] resistant to PARP [inhibitors], but are also resistant to platinum[-based chemotherapy]. It’s a huge unmet clinical need to identify treatments that are effective for patients progressing during PARP [inhibitor therapy].”

    In the interview, Lorusso discussed the background of the ROSELLA trial, efficacy and safety data from the study, potential clinical implications, and next steps for evaluating the relacorilant-based regimen.

    Lorusso is the director of the Gynecological Oncology Unit at Humanitas Hospital San Pio X in Milan, as well as a full professor of Obstetrics and Gynecology at Humanitas University in Rozzano, Italy.

    OncLive: What was the rationale and design of the ROSELLA trial?

    Lorusso: We have discovered that glucocorticoid receptor signaling can reduce sensitivity to chemotherapy. Preclinical and early clinical data suggest that ovarian cancer expresses the glucocorticoid receptor, which is a marker of poor prognosis. The data suggest that when cortisol activates the glucocorticoid receptor, it can induce the transcription of anti-apoptotic genes that are involved in epithelial-mesenchymal transition and resistance to chemotherapy. This is why targeting this receptor with relacorilant, a selective glucocorticoid receptor antagonist, is interesting. We have phase 2 data suggesting that when we combine intermittent relacorilant with nab-paclitaxel, we can increase PFS and overall survival [OS] in platinum-resistant ovarian cancer. We chose nab-paclitaxel instead of weekly paclitaxel, which is more commonly used in ovarian cancer because nab-paclitaxel does not require corticosteroid premedication. Because relacorilant is a glucocorticoid receptor antagonist, we only combine drugs that do not require a glucocorticoid receptor.

    The ROSELLA trial is a randomized phase 3 trial comparing nab-paclitaxel with relacorilant plus nab-paclitaxel in platinum-resistant and refractory patients, [which we defined as] patients [whose disease] progressed between 1 and 3 months [after] prior platinum[-based therapy]. We are analyzing the data of the efficacy of the drug in patients progressing during PARP [inhibitor therapy]. These patients could not have received more than 3 prior lines of therapy, and prior bevacizumab [Avastin] was required. The trial has 2 primary end points: PFS, as evaluated according to RECIST 1.1 criteria by a blinded independent central review, and OS.

    What were the key efficacy data?

    The trial met its primary [PFS] end point, [with] a significant increase in PFS reported in patients treated with relacorilant/nab-paclitaxel. The median PFS was 5.5 months with nab-paclitaxel vs 6.5 months with relacorilant plus nab-paclitaxel. The HR was 0.70, suggesting a 30% reduction in the risk of [disease] progression [or death]. [Data from] the interim analysis for OS [showed that] the median OS increased from 11.5 months in the nab-paclitaxel arm to 15.97 months in the relacorilant plus nab-paclitaxel arm, with a HR of 0.69. [These data are] not yet mature; we have to wait for the final OS data.

    Interestingly, there was a slight improvement in overall response rate [ORR], [with a] 7% improvement. [The ORR was] 30.1% with nab-paclitaxel and 36.9% with relacorilant plus nab-paclitaxel. [Regarding] the clinical benefit rate, there was a 12% [improvement with the relacorilant combination].

    What was the safety profile of relacorilant in this study?

    The safety profile of the drug was manageable. The most frequently reported adverse effects [AEs] were neutropenia, anemia, and fatigue in patients treated with the relacorilant plus nab-paclitaxel arm. Hematologic AEs included neutropenia and anemia. [Interestingly], the duration of exposure was different in patients receiving nab-paclitaxel or nab-paclitaxel plus relacorilant. When we adjusted the hematological toxicity of neutropenia and anemia for the duration of exposure, the incidence and rates of neutropenia and anemia were very comparable between the 2 treatment arms. We can conclude that the toxicity profile is mainly hematological, but manageable.

    What are the potential clinical implications of these findings?

    [Nab-paclitaxel plus relacorilant] can be easily considered a new SOC for our patient with platinum-resistant and refractory ovarian cancer. [What was interesting about] the trial is that the comparator arm was nab-paclitaxel. According to the indirect trial comparison data we have, [this is] as effective as weekly paclitaxel, [which] we consider [to be] the most effective drug in the platinum-resistant setting. What we demonstrate with the ROSELLA trial is that when we add relacorilant to the best drug in the platinum-resistant setting, we further increase PFS.

    What future investigations are planned based on this research?

    We are now running the BELLA trial [NCT06906341], which is a single-arm phase 2 trial combining nab-paclitaxel and relacorilant with bevacizumab. In the ROSELLA trial, all the patients should have received prior bevacizumab; therefore, we only have the data of nab-paclitaxel plus relacorilant. In the BELLA trial, we have both cohorts: the patients who have previously received bevacizumab, and patients who have not previously received bevacizumab. All these patients are treated with the triplet regimen of nab-paclitaxel, relacorilant, and bevacizumab.

    Reference

    Lorusso D, Gladieff L, Gilbert L, et al. Phase III results of relacorilant + nab-paclitaxel vs nab-paclitaxel in platinum-resistant ovarian cancer (PROC) (ROSELLA, GOG-3073, ENGOT-ov72): secondary endpoints. Ann Oncol. 2025;10(suppl 5):105332. doi:10.1016/j.esmoop.2025.105332

    Continue Reading